

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non- small-cell lung cancer after platinum-based chemoradiotherapy

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | | |
|---|--|
| 1. | Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| A consultee raised that EGFR mutations are more commonly found in females and people with East Asian or Bangladeshi, Indian or Pakistani ethnicity. The committee considered that issues of differing disease prevalence cannot be addressed in a technology appraisal. | |

- | | |
|-----|---|
| 2. | Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| No. | |

- | | |
|-----|---|
| 3. | Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
| No. | |

4.	Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.	

5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.	

6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
No.	

7.	Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
Yes – section 3.20.	

Approved by Associate Director (name): Ian Watson

Date: 19 July 2025